Stem cell mobilization and transplantation represent pivotal advances in the management of multiple myeloma. This therapeutic approach involves stimulating the release of haematopoietic stem cells ...

In addition to multiple myeloma and a planned Phase 1 study in acute myeloid leukemia (AML) patients, the company is also in discussions for potential collaborations that would utilize GPC-100’s rapid ...

Burixafor is an investigational small molecule that blocks CXCL12 binding to CXCR4 receptors on HPCs, rapidly mobilizing these cells from the bone marrow into the peripheral blood. In preclinical ...

ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable ...

An expert sat down with CURE® and discussed how stem cells are collected before a patient with myeloma undergoes a stem cell transplant. A stem cell transplant is one of the most efficient tools to ...

Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A real-world analysis presented at the American Society of ...

TEL AVIV, Israel and WALTHAM, Mass., Sept. 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in ...

Impact of glucagon-like peptide-1 receptor agonists on morbidity and mortality in multiple myeloma patients with type 2 diabetes mellitus: A retrospective cohort analysis. This is an ASCO Meeting ...

Among patients who were newly diagnosed with multiple myeloma, Kyprolis (carfilzomib) plus Revlimid (lenalidomide) and dexamethasone (KRd) was associated with improvements in progression-free survival ...

Key Highlights Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies 90% (9 of 10) of ...